Page 51 - 南京医科大学学报自然科学版
P. 51

第43卷第1期         花   颖,刘文世,郑冬冬,等. 先天性心脏病相关肺动脉高压血清IL⁃32的变化与肺动脉压相
                2023年1月                关性研究[J]. 南京医科大学学报(自然科学版),2023,43(01):040-045                     · 45  ·


                诊断的价值。ROC 曲线分析发现,当 IL⁃32 截断值                           志,2021,101(1):11-51
                取 58.49 pg/mL 时,诊断 PAH 的灵敏度为 62%,特异              [9] SIMONNEAU G,MONTANI D,CELERMAJER D S,et al.
                度高达92%。越来越多的证据表明,多种生物标志                                Haemodynamic definitions and updated clinical classifica⁃
                物联合有利于获取疾病更准确的信息,因此我们进                                 tion of pulmonary hypertension[J]. Eur Respir J,2019,53
                                                                      (1):1801913-1801926
                一步研究了 IL⁃32 联合 BNP 诊断 PAH 的价值,发现
                                                                 [10] SANTOS⁃GOMES J,GANDRA I,ADÃO R. An overview
                IL⁃32 诊断 PAH 的效能不劣于 BNP,尽管 BNP 联合
                                                                       of circulating pulmonary arterial hypertension biomarkers
                IL⁃32的AUC与单独使用BNP的AUC无统计学差异
                                                                      [J]. Front Cardiovasc Med,2022,9:924873
               (P > 0.05),但其具有更高的灵敏度、阳性预测值和
                                                                 [11] WANG R R,YUAN T Y,WANG J M,et al. Immunity and
                阴性预测值。                                                 inflammation in pulmonary arterial hypertension:from
                    本研究还存在一些局限性。首先,这是一项单                               pathophysiology mechanisms to treatment perspective[J].
                中心研究,需要扩大样本量。其次,本研究所用试                                 Pharmacol Res,2022,180:106238
                剂盒能够识别 IL⁃32 的 3 种主要亚型(α、β和γ),但                  [12] ROSS D,STRIETER R,FISHBEIN M,et al. Type I im⁃

                不能细分,后续的研究需探讨不同亚型在CHD⁃PAH                              mune response cytokine⁃chemokine cascade is associated
                中的含量及作用。                                               with pulmonary arterial hypertension[J]. J Heart,2012,
                                                                       31(8):865-873
               [参考文献]
                                                                 [13] GEORGE P M,OLIVER E,DORFMULLER P,et al. Evi⁃
               [1] STOUT K K,DANIELS C J,ABOULHOSN J A,et al.          dence for the involvement of type I interferon in pulmo⁃
                    2018 AHA/ACC guideline for the management of adults  nary arterial hypertension[J]. Circ Res,2014,114(4):
                    with congenital heart disease:a report of the American  677-688
                    college of cardiology/American heart association task  [14] RAJKUMAR S,PULLAMSETTI S S,JULIA K,et al. Im⁃
                    force on clinical practice guidelines[J]. J Am Coll Cardi⁃  mune and inflammatory cell involvement in the pathology
                    ol,2019,73(12):e81-e192                            of idiopathic pulmonary arterial hypertension[J]. Am J
               [2] BAUMGARTNER H,DE BACKER J. The ESC clinical         Respir Crit Care Med,2012,186(9):897-908
                    practice guidelines for the management of adult congeni⁃  [15] NOLD⁃PETRY C A,NOLD M F,NOLD M F,et al. IL⁃32⁃
                    tal heart disease 2020[J]. Eur Heart J,2020,41(43):  dependent effects of IL⁃1beta on endothelial cell functions
                    4153-4154                                         [J]. PNAS,2009,106(10):3883-3888
               [3] PAPAMICHALIS M,XANTHOPOULOS A,PAPAMICH⁃       [16] AASS K,KASTNES M,STANDAL T. Molecular interac⁃
                    ALIS P,et al. Adult congenital heart disease with pulmo⁃  tions and functions of IL ⁃ 32[J]. J Leukoc Biol,2021,
                    nary arterial hypertension:mechanisms and management  109:143-159
                    [J]. Heart Fail Rev,2020,25(5):773-794       [17] XIN T,CHEN M,DUAN L,et al. Interleukin⁃32:its role
               [4] HOU Y,WEN L,SHU T,et al. Efficacy and safety of pul⁃  in asthma and potential as a therapeutic agent[J]. Respir
                    monary vasodilators in the patients with Eisenmenger syn⁃  Res,2018,19(1):124
                    drome:a meta⁃analysis of randomized controlled trials[J].  [18] AWAD K S,WEST J D,DE JESUS PEREZ V,et al. Novel
                    Pulm Circ,2021,11(2):20458940211015823
                                                                       signaling pathways in pulmonary arterial hypertension
               [5] 周婷婷,乔凤杰,潘         宇,等. IL⁃32 在恶性肿瘤中的研
                                                                      (2015 Grover Conference Series)[J]. Pulm Circ,2016,6
                    究进展[J]. 南京医科大学学报(自然科学版),2020,40                   (3):285-294
                    (2):298-302
                                                                 [19] MARON B A,WERTHEIM B M,GLADWIN M T. Under
               [6] NOLD⁃PETRY C A,RUDLOFF I,BAUMER Y,et al. IL⁃
                                                                       pressure to clarify pulmonary hypertension clinical risk
                    32 promotes angiogenesis[J]. J Immunol,2014,192(2):
                                                                      [J]. Am J Respir Crit Care Med,2018,197(4):423-426
                    589-602
                                                                 [20] DICKINSON M G,BARTELDS B,BORGDORFF M A,et
               [7] DI BENEDETTO P,GUGGINO G,MANZI G,et al. Inter⁃
                                                                       al. The role of disturbed blood flow in the development of
                    leukin⁃32 in systemic sclerosis,a potential new biomarker  pulmonary arterial hypertension:lessons from preclinical
                    for pulmonary arterial hypertension[J]. Arthritis Res  animal models[J]. Am J Physiol Lung Cell Mol Physiol,
                    Ther,2020,22(1):127-136
                                                                       2013,305(1):L1-L14
               [8] 中华医学会呼吸病学会肺柱塞与肺血管病学组. 中国                                                 [收稿日期] 2022-04-13
                    肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂                                               (责任编辑:蒋 莉)
   46   47   48   49   50   51   52   53   54   55   56